Table 1.
Patients characteristics.
| All patients | Ommaya | LP | p | |
|---|---|---|---|---|
| Gender | n = 40 %(n) | 10 (25) | 30 (75) | 0.251 |
| Male | 26 (65) | 5 (50) | 21(70) | |
| Female | 14 (35) | 5 (50) | 9 (30) | |
| Age in years, median (range) | 52 (18-76) | 50 (18-64) | 54.5 (20-76) | 0.168 (Xi2) 0.033 (Fisher) |
| KPS, median (range) | 70 (40-100) | 70 (50-100) | 70 (40-100) | 0.580 |
| PRIMARY TUMOR | ||||
| •Breast | 10 (25) | 3 (30) | 7 (23.33) | |
| •Lung | 7 (17.5) | 0 (0) | 7 (23.33) | |
| •Leukemia | 7(17.5) | 2 (20) | 5 (16.67) | |
| •Melanoma | 5 (12.5) | 0 (0) | 5 (16.67) | |
| •Ovary | 4 (10) | 2 (20) | 2 (6.67) | |
| •Prostate | 3 (7.5) | 1 (10) | 2 (6.67) | |
| •Lymphoma | 2 (5) | 1 (10) | 1 (3.33) | |
| •Unknown | 2 (5) | 1 (10) | 1(3.33) | |
| TREATMENT REGIMEN | ||||
| •Ara-C | 7 (17.5) | 1 (10) | 6 (20) | 0.846 |
| •Mtx | 5 (12.5) | 1(10) | 4 (13.33) | |
| •Mtx/Ara | 28 (70) | 8 (80) | 20 (66.67) | |
| Overall survival (OS in months) | 0.4 – 10 | 3-10 | 0.4-7.1 | 0.0006 |
KPS, Karnofsky Performance Status; LP, Lumbar puncture; Ara-C, Citarabine; Mtx: Methotrexate.